Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors

a technology of n-hydroxylsulfonamide and nitroxyl, which is applied in the field of n-hydroxylsulfonamide derivatives, can solve the problems of exercise intolerance, subsequent decline in heart function, and heart failure, and achieve the effects of increasing ischemia/reperfusion injury, controlling vascular tone, and protecting against myocardial ischemia/reperfusion injury

Inactive Publication Date: 2011-12-15
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF0 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]Despite efforts towards the development of new therapies for the treatment of diseases and conditions such as heart failure and ischemia / reperfusion injury, there remains a significant interest in and need for additional or alternative compounds that treat or prevent the onset or severity of these and related diseases or conditions. In particular, there remains a significant medical need for alternative or additional therapies for the treatment of diseases or conditions that are responsive to nitroxyl therapy. New compounds that donate nitroxyl under physiological conditions and methods of using compounds that donate nitroxyl under physiological conditions may thus find use as therapies for treating, preventing and / or delaying the onset and / or development of diseases or conditions responsive to nitroxyl therapy, including heart disease and ischemia / reperfusion injury. Preferably, the therapeutic agents can improve the quality of life and / or prolong the survival time for patients with the disease or condition.BRIEF SUMMARY OF THE INVENTION

Problems solved by technology

Symptoms include breathlessness, fatigue, weakness, leg swelling, and exercise intolerance.
Ultimately, such blockages may cause myocardial infarction with subsequent decline in heart function and resultant heart failure.
The effects of CHF on a subject experiencing the condition can be fatal.
Systolic heart failure occurs when the heart's ability to contract decreases.
Diastolic heart failure refers to the heart's inability to relax between contractions and allow enough blood to enter the ventricles.
Swelling (edema) in the abdomen and legs is a typical symptom of diastolic heart failure.
Often, an individual experiencing heart failure will have some degree of both systolic heart failure and diastolic heart failure.
Acute CHF can be caused by acute myocardial injury that affects either myocardial performance, such as myocardial infarction, or valvular / chamber integrity, such as mitral regurgitation or ventricular septal rupture, which leads to an acute rise in left ventricular and diastolic pressure resulting in pulmonary edema and dyspnea.
However, use of a beta-agonist has potential complications, such as arrhythmogenesis and increased oxygen demand by the heart.
Additionally, the initial short-lived improvement of myocardial contractility afforded by these drugs is followed by an accelerated mortality rate resulting largely from a greater frequency of sudden death.
However, even subjects that improve under beta-antagonist therapy may subsequently decompensate and require acute treatment with a positive inotropic agent.
Unfortunately, as their name suggests, beta-antagonists block the mechanism of action of the positive inotropic beta-agonists that are used in emergency care centers.
However, this combined administration can impair the effectiveness of positive inotropic treatment agents.
Ischemia is a condition characterized by an interruption or inadequate supply of blood to tissue, which causes oxygen deprivation in the affected tissue.
The blockade or constriction causes oxygen deprivation of the non-perfused tissue, which can cause tissue damage.
Further, upon reperfusion with subsequent reoxygenation of the tissue, when the blood is able to flow again or the oxygen demand of the tissue subsides, additional injury can be caused by oxidative stress.
The effects of ischemia / reperfusion injury in a subject experiencing the condition can be fatal, particularly when the injury occurs in a critical organ such as the heart or brain.
However, the chemical stability of AS has made it unsuitable to develop as a therapeutic agent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
  • N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
  • N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Compounds According to General Synthesis of Scheme A

[0116]The preparation of 2-bromo-N-hydroxy-benezene-sulfonamide is detailed below as a representative example of the synthetic method exemplified in Scheme A.

[0117]To a solution of hydroxylamine hydrochloride (0.82 g, 0.012 mol) in water (1.2 ml) at 0° C. was added a solution of potassium carbonate (1.6 g, 0.012 mol) in water (1.8 ml) dropwise maintaining an internal reaction temperature between 5° C. and 15° C. The reaction mixture was stirred for 15 minutes, whereupon THF (6 ml) and MeOH (1.5 ml) were added. 2-Bromobenzene sulfonyl chloride (1.51 g, 0.006 mol) was added portionwise maintaining a temperature below 15° C. and the reaction mixture was stirred at ambient temperature until complete consumption of the sulfonyl chloride was observed by TLC. The resulting suspension was concentrated to remove any volatiles and the aqueous suspension was extracted with diethyl ether (2×100 ml). The organic portion was dried...

example 2

Preparation of Compounds According to General Synthesis of Scheme B

[0131]The preparation of N-benzyloxy-2-bromo-benzenesulfonamide

is detailed below as a representative example of the synthetic method exemplified in Scheme B.

[0132]To a suspension of O-benzylhydroxylamine hydrochloride (3.75 g, 23.48 mmol) in MeOH (3 ml) and water (3.6 ml) was added a solution of potassium carbonate (3.24 g, 23.48 mmol) in water (3.6 ml), maintaining an internal reaction temperature below 10° C. The reaction mixture was stirred for 5 minutes, whereupon THF (12 ml) and 2-bromobenzene sulfonyl chloride (3 g, 11.74 mmol) were added. The reaction mixture was stirred at ambient temperature until complete consumption of the sulfonyl chloride was observed by TLC. The resulting suspension was concentrated in vacuo to remove any volatiles, and the aqueous suspension was extracted with diethyl ether (3×100 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to yield the crud...

example 3

Preparation of Compounds According to General Synthesis of Scheme C

[0137]The preparation of 4-Bromo-N-(tetrahydro-pyran-2-yloxy)-benzenesulfonamide

is detailed below as a representative example of the synthetic method exemplified in Scheme C.

[0138]To a solution of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.83 g, 15.65 mmol) in water (1.6 ml) at 0° C. was added a solution of potassium carbonate (1.1 g, 7.83 mmol) in water (2.4 ml) dropwise maintaining an internal reaction temperature below 10° C. After 15 minutes MeOH (2 ml) and THF (8 ml) were added was dropwise, followed by 4-bromobenzene sulfonyl chloride (2 g, 7.83 mmol) portionwise. The reaction mixture was stirred at ambient temperature until complete consumption of the sulfonyl chloride was observed by TLC. The resulting suspension was concentrated to remove any volatiles and the aqueous suspension was extracted with diethyl ether (3×100 ml). The organic portion was dried over sodium sulfate, filtered and concentrated in vacu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and / or preventing the onset and / or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia / reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application Ser. No. 60 / 783,556, filed Mar. 17, 2006 and entitled “N-Hyroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Doners,” which is incorporated herein by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made in part with government support under Grant No. CHE-0518406 from the National Science Foundation. The government may have certain rights in this invention.BACKGROUND OF THE INVENTIONSummary of Heart Failure[0003]Congestive heart failure (CHF) is a generally progressive, life threatening condition in which myocardial contractility is depressed such that the heart is unable to adequately pump the blood returning to it, also referred to as decompensation. Symptoms include breathlessness, fatigue, weakness, leg swelling, and exercise intolerance. On physical examination, patients with heart...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377C07D295/135A61K31/185A61K31/5375A61K31/495A61K31/4453C07D307/82C07D333/62C07D215/36C07D235/28C07D277/80C07D263/58A61K31/343A61K31/381A61K31/47A61K31/4184A61K31/427A61K31/423C07D333/34C07D413/04C07D241/14A61K31/4965A61P9/00A61P9/04C07C311/48
CPCC07D213/74C07D261/10C07D263/58C07D285/125C07D295/096C07D309/12C07D333/62C07C311/48C07C317/14C07C323/67C07D307/82C07D231/18C07D333/34C07D317/14A61P11/00A61P3/06A61P43/00A61P7/10A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P3/10A61K31/18C07D207/36C07D233/84C07D307/02C07D333/18Y02A50/30
Inventor TOSCANO, JOHN P.BROOKFIELD, FREDERICK ARTHURCOHEN, ANDREW D.COURTNEY, STEPHEN MARTINFROST, LISA MARIEKALISH, VINCENT JACOB
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com